Brand name- Orgovyx
Generic name- relugolix
Manufactured by: Bushu Pharmaceuticals, Ltd, Kawagoe, Saitama, Japan
Manufactured for: Myovant Sciences, Inc., Brisbane, CA 94005
Dosage Form- oral or tablet
Strength- 120mg
Composition- relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg
Packaging- 120 mg tablets, film-coated, light red, almond-shaped; supplied in two configurations, bottles and blister packs.
Indication- Approved for the treatment of adult patients with advanced prostate cancer.
Storage- Store at room temperature. Don’t store above 30°C (86°F).
Description:
Relugolix is a nonpeptide small molecule, GnRH receptor antagonist. The molecular weight is 623.63 daltons and the molecular formula is C29H27F2N7O5S.
The GnRH receptor regulates the production of hormones. It is mainly responsible for making follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These hormones are vital for producing and controlling the levels of testosterone in the human body.
Pharmacodynamics
Pituitary and Gonadal Hormones- Relugolix reduced LH, FSH, and testosterone concentrations after oral administration of the recommended loading dose of 360 mg and a 120 mg dose once daily. Out of 622 patients, 56% had testosterone concentrations at castrate levels (< 50 ng/dL) by the first sampling time point at Day 4, and 97% maintained castrate levels of testosterone through 48 weeks. In a substudy of 137 patients who did not receive subsequent androgen deprivation therapy for at least 90 days after discontinuation of relugolix, the cumulative incidence rate of achieving testosterone concentrations above the lower limit of the normal range (> 280 ng/dL) or baseline at 90 days was 55%.
Cardiac Electrophysiology- In a randomized, double-blind, placebo- and positive-controlled (open-label moxifloxacin), parallel group thorough QT/QTc study, no increase in mean QTc interval > 10 ms was identified after administration of single 60 or 360 mg doses of relugolix (0.2 or 1 times the recommended loading dose, respectively).
Ingredients
The active ingredient of Orgovyx is relugolix, where relugolix is a gonadotropin-releasing hormone antagonist (GnRH receptor antagonist) medication. The inactive ingredients of Orgovyx are mannitol, sodium starch glycolate, hydroxypropyl cellulose, magnesium stearate, hypromellose, titanium dioxide, ferric oxide red and carnauba wax.
Usage Of Medicine
As announced by Myovant Sciences, OrgovyxTM is the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, approved by the US Food and Drug Administration for the treatment of adult patients with Advanced Prostate Cancer.


